Loading...

GlycoMimetics

DB:GKO
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GKO
DB
$517M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
GKO Share Price and Events
7 Day Returns
-1.5%
DB:GKO
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-27.8%
DB:GKO
-9.2%
DE Biotechs
-6.7%
DE Market
GKO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GlycoMimetics (GKO) -1.5% -4.3% 14.3% -27.8% 92.1% 7.8%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • GKO underperformed the Biotechs industry which returned -9.2% over the past year.
  • GKO underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
GKO
Industry
5yr Volatility vs Market
Related Companies

Value

 Is GlycoMimetics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of GlycoMimetics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for GlycoMimetics.

DB:GKO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:GKO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:GKO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for GlycoMimetics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:GKO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -35.35 Analyst x2 -32.73
2020 -35.70 Analyst x2 -30.60
2021 -57.15 Analyst x2 -45.36
2022 -9.35 Analyst x2 -6.87
2023 51.05 Analyst x2 34.73
2024 79.84 Est @ 56.39% 50.29
2025 111.40 Est @ 39.54% 64.97
2026 142.32 Est @ 27.75% 76.84
2027 170.05 Est @ 19.49% 85.01
2028 193.37 Est @ 13.71% 89.49
Present value of next 10 years cash flows $285.76
DB:GKO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $193.37 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$2,490.87
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,490.87 ÷ (1 + 8.01%)10
$1,152.80
DB:GKO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $285.76 + $1,152.80
$1,438.56
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,438.56 / 43.17
$33.32
DB:GKO Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:GKO represents 0.86044x of NasdaqGM:GLYC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86044x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 33.32 x 0.86044
€28.67
Value per share (EUR) From above. €28.67
Current discount Discount to share price of €10.42
= -1 x (€10.42 - €28.67) / €28.67
63.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price GlycoMimetics is available for.
Intrinsic value
>50%
Share price is €10.42 vs Future cash flow value of €28.67
Current Discount Checks
For GlycoMimetics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • GlycoMimetics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • GlycoMimetics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GlycoMimetics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GlycoMimetics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GKO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.18
NasdaqGM:GLYC Share Price ** NasdaqGM (2019-04-18) in USD $12.11
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GlycoMimetics.

DB:GKO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:GLYC Share Price ÷ EPS (both in USD)

= 12.11 ÷ -1.18

-10.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GlycoMimetics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • GlycoMimetics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does GlycoMimetics's expected growth come at a high price?
Raw Data
DB:GKO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
36.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GlycoMimetics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GlycoMimetics's assets?
Raw Data
DB:GKO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.76
NasdaqGM:GLYC Share Price * NasdaqGM (2019-04-18) in USD $12.11
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:GKO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:GLYC Share Price ÷ Book Value per Share (both in USD)

= 12.11 ÷ 4.76

2.54x

* Primary Listing of GlycoMimetics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GlycoMimetics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess GlycoMimetics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GlycoMimetics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GlycoMimetics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GlycoMimetics expected to grow at an attractive rate?
  • GlycoMimetics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • GlycoMimetics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare GlycoMimetics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:GKO Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GKO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 36.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GKO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GKO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 183 154 6
2022-12-31 114 53 6
2021-12-31 42 -21 -57 6
2020-12-31 5 -44 -70 4
2019-12-31 12 -63 -54 7
DB:GKO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -43 -48
2018-09-30 -42 -44
2018-06-30 -38 -40
2018-03-31 -31 -37
2017-12-31 -30 -33
2017-09-30 0 -27 -32
2017-06-30 0 -29 -32
2017-03-31 0 -30 -32
2016-12-31 0 -30 -32
2016-09-30 0 -31 -32
2016-06-30 0 -10 -32
2016-03-31 20 -9 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • GlycoMimetics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if GlycoMimetics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GKO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from GlycoMimetics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GKO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.10 3.56 2.63 2.00
2022-12-31 1.06 1.16 0.95 2.00
2021-12-31 -1.22 -0.67 -1.97 6.00
2020-12-31 -1.51 -1.23 -1.86 5.00
2019-12-31 -1.25 -0.22 -1.82 7.00
DB:GKO Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.18
2018-09-30 -1.12
2018-06-30 -1.10
2018-03-31 -1.14
2017-12-31 -1.13
2017-09-30 -1.21
2017-06-30 -1.33
2017-03-31 -1.44
2016-12-31 -1.50
2016-09-30 -1.60
2016-06-30 -1.65
2016-03-31 -0.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GlycoMimetics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess GlycoMimetics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GlycoMimetics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GlycoMimetics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GlycoMimetics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GlycoMimetics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare GlycoMimetics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GlycoMimetics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GlycoMimetics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GlycoMimetics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GKO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -48.27 11.41 40.09
2018-09-30 -43.62 11.31 34.77
2018-06-30 -40.00 10.92 30.82
2018-03-31 -36.86 10.60 27.24
2017-12-31 -33.28 9.83 24.10
2017-09-30 0.00 -32.35 9.31 23.44
2017-06-30 0.02 -32.26 8.90 23.58
2017-03-31 0.02 -32.19 8.69 23.64
2016-12-31 0.02 -31.81 8.65 23.28
2016-09-30 0.05 -32.36 8.31 24.18
2016-06-30 0.04 -31.68 8.46 23.30
2016-03-31 20.07 -13.22 7.96 25.36
2015-12-31 20.07 -12.77 7.81 25.05
2015-09-30 20.04 -11.28 7.96 23.37
2015-06-30 20.04 -10.73 7.48 23.38
2015-03-31 15.03 -13.13 7.28 20.90
2014-12-31 15.03 -11.12 6.60 19.57
2014-09-30 15.10 -7.60 5.30 17.41
2014-06-30 15.16 -4.68 4.45 15.31
2014-03-31 0.19 -16.17 3.52 12.84
2013-12-31 3.99 -10.61 2.90 11.70
2013-09-30 7.80 -6.10 2.59 11.31
2013-06-30 11.58 -1.58 2.34 10.81
2013-03-31 15.29 3.02 2.22 10.05
2012-12-31 15.26 3.66 2.18 9.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GlycoMimetics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GlycoMimetics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GlycoMimetics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GlycoMimetics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GlycoMimetics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GlycoMimetics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GlycoMimetics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GlycoMimetics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GlycoMimetics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GlycoMimetics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • GlycoMimetics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GlycoMimetics Company Filings, last reported 3 months ago.

DB:GKO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 205.46 0.00 209.92
2018-09-30 218.10 0.00 219.83
2018-06-30 227.99 0.00 229.43
2018-03-31 238.04 0.00 242.63
2017-12-31 119.70 0.00 123.92
2017-09-30 108.56 0.00 112.87
2017-06-30 115.43 0.00 119.15
2017-03-31 31.89 0.00 34.60
2016-12-31 35.30 0.00 40.05
2016-09-30 41.75 0.00 45.28
2016-06-30 48.88 0.00 53.09
2016-03-31 34.77 0.00 38.84
2015-12-31 40.47 0.00 46.81
2015-09-30 48.70 0.00 53.77
2015-06-30 55.22 0.00 40.25
2015-03-31 44.36 0.00 46.58
2014-12-31 50.80 0.00 55.22
2014-09-30 57.71 0.00 61.36
2014-06-30 63.88 0.00 66.22
2014-03-31 55.35 0.00 56.97
2013-12-31 2.91 0.00 2.31
2013-09-30 6.52 0.00 7.69
2013-06-30 9.74 0.00 10.78
2013-03-31 12.53 0.00 17.37
2012-12-31 12.53 0.00 17.37
  • GlycoMimetics has no debt.
  • GlycoMimetics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GlycoMimetics has sufficient cash runway for more than 3 years based on current free cash flow.
  • GlycoMimetics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 38.3% each year.
X
Financial health checks
We assess GlycoMimetics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GlycoMimetics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GlycoMimetics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GlycoMimetics dividends.
If you bought €2,000 of GlycoMimetics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GlycoMimetics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GlycoMimetics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GKO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GKO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GlycoMimetics has not reported any payouts.
  • Unable to verify if GlycoMimetics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GlycoMimetics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GlycoMimetics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess GlycoMimetics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GlycoMimetics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GlycoMimetics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GlycoMimetics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rachel King
COMPENSATION $1,555,300
AGE 59
TENURE AS CEO 16.3 years
CEO Bio

Mrs. Rachel K. King co-founded Glycomimetics, Inc. in 2003 and has been its Chief Executive Officer and its President since 2003. She has been a Director of Novavax, Inc. since November 1, 2018. Mrs. King joined the Novavax Board in 2018. Mrs. King served as an Executive in Residence at New Enterprise Associates (NEA) from 2001 to 2003. She served as a Senior Vice President of Novartis Corporation from 1999 to 2001. She served as an executive with Genetic Therapy, Inc. for ten years. At GTI, Mrs. King held various roles, including serving as its Chief Executive Officer. Mrs. King worked at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She serves as a Vice Chairman of Health Section at the Biotechnology Industry Organization (BIO). She serves as a Director of Biotechnology Innovation Organization. She has been a Director of Warp Drive Bio, LLC since July 2016. She serves on the Dean's Council of the Harvard School of Public Health and on the Board of Imagination Stage. She has been a Director of GlycoMimetics, Inc. since 2003. She served as a Director of MDBio, Inc. Mrs. King received her B.A. degree from Dartmouth College and her MBA degree from Harvard Business School. She served as Chair of the Maryland Life Sciences Advisory Board from 2013 to 2015. She also serves on the Board of the University of Maryland BioPark.

CEO Compensation
  • Rachel's compensation has increased whilst company is loss making.
  • Rachel's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the GlycoMimetics management team in years:

10.3
Average Tenure
50
Average Age
  • The average tenure for the GlycoMimetics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rachel King

TITLE
President
COMPENSATION
$2M
AGE
59
TENURE
16.3 yrs

Brian Hahn

TITLE
Senior VP
COMPENSATION
$798K
AGE
44
TENURE
7.3 yrs

John Magnani

TITLE
Senior VP of Research
COMPENSATION
$884K
AGE
65
TENURE
16.3 yrs

Helen Thackray

TITLE
Senior VP of Clinical Development & Chief Medical Officer
COMPENSATION
$935K
AGE
50
TENURE
13.3 yrs

Henry Flanner

TITLE
Vice President of Technical Operations
TENURE
2.8 yrs

Armand Girard

TITLE
Senior Vice President of Strategy and Corporate Development
AGE
49
TENURE
5 yrs
Board of Directors Tenure

Average tenure and age of the GlycoMimetics board of directors in years:

3.9
Average Tenure
64
Average Age
  • The tenure for the GlycoMimetics board of directors is about average.
Board of Directors

Jim Barrett

TITLE
Chairman
COMPENSATION
$175K
AGE
76

Rachel King

TITLE
President
COMPENSATION
$2M
AGE
59
TENURE
16.3 yrs

John Magnani

TITLE
Senior VP of Research
COMPENSATION
$884K
AGE
65
TENURE
16.3 yrs

Tim Pearson

TITLE
Director
COMPENSATION
$160K
AGE
50
TENURE
5.1 yrs

Mark Goldberg

TITLE
Director
COMPENSATION
$152K
AGE
64
TENURE
4.8 yrs

Dan Junius

TITLE
Director
COMPENSATION
$150K
AGE
66
TENURE
3.1 yrs

Scott Koenig

TITLE
Director
COMPENSATION
$232K
AGE
66
TENURE
2.1 yrs

Pat Andrews

TITLE
Director
COMPENSATION
$199K
AGE
59
TENURE
1.8 yrs

Scott Jackson

TITLE
Director
AGE
53
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Jun 18 Sell Brian Hahn Individual 11. Jun 18 11. Jun 18 -14,085 €15.28 €-215,192
X
Management checks
We assess GlycoMimetics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GlycoMimetics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Details
Name: GlycoMimetics, Inc.
GKO
Exchange: DB
Founded: 2003
$459,685,284
43,168,969
Website: http://www.glycomimetics.com
Address: GlycoMimetics, Inc.
9708 Medical Center Drive,
Rockville,
Maryland, 20850,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM GLYC Common Stock Nasdaq Global Market US USD 10. Jan 2014
DB GKO Common Stock Deutsche Boerse AG DE EUR 10. Jan 2014
Number of employees
Current staff
Staff numbers
50
GlycoMimetics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:04
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.